Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
268664
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**268664** is an investigational prophylactic Epstein-Barr virus vaccine developed by Henogen in collaboration with GSK. It is a recombinant protein-subunit vaccine containing EBV glycoprotein 350 and formulated with the AS04 adjuvant system, comprising aluminum hydroxide and 3-O-desacyl-4′-monophosphoryl lipid A. The vaccine was evaluated as a three-dose intramuscular regimen in EBV-seronegative adolescents and young adults to prevent infectious mononucleosis. In a completed Phase 2 randomized trial, it reduced infectious mononucleosis associated with primary EBV infection but did not prevent asymptomatic EBV infection. ([orbi.uliege.be](https://orbi.uliege.be/bitstream/2268/71471/1/Recombinant%20gp350%20vaccine%20for%20infectious%20mononucleosis%20-%202007.pdf))
- Other names
- EBV vaccine (268664)GSK Biologicals' EBV vaccine (268664)gp350/AS04 vaccine
02
Targets
gp350 (Epstein-Barr virus glycoprotein 350)
Beyond the preview
Go deeper on 268664.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 268664.